[HTML][HTML] The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019
EM Alvarez, LM Force, R Xu, K Compton, D Lu… - The Lancet …, 2022 - thelancet.com
Background In estimating the global burden of cancer, adolescents and young adults with
cancer are often overlooked, despite being a distinct subgroup with unique epidemiology …
cancer are often overlooked, despite being a distinct subgroup with unique epidemiology …
Testicular cancer
Testicular cancer is the most common malignancy among men between 14 and 44 years of
age, and its incidence has risen over the past two decades in Western countries. Both …
age, and its incidence has risen over the past two decades in Western countries. Both …
Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion …
SM Yoon, BY Ryoo, SJ Lee, JH Kim, JH Shin… - JAMA …, 2018 - jamanetwork.com
Importance Patients with hepatocellular carcinoma showing macroscopic vascular invasion
have a poor prognosis. Sorafenib is the sole treatment option for these patients, with …
have a poor prognosis. Sorafenib is the sole treatment option for these patients, with …
Oral mucosal organoids as a potential platform for personalized cancer therapy
E Driehuis, S Kolders, S Spelier, K Lõhmussaar… - Cancer discovery, 2019 - AACR
Previous studies have described that tumor organoids can capture the diversity of defined
human carcinoma types. Here, we describe conditions for long-term culture of human …
human carcinoma types. Here, we describe conditions for long-term culture of human …
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
[HTML][HTML] Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with …
M Kudo, RS Finn, J Edeline, S Cattan… - European Journal of …, 2022 - Elsevier
Objective Pembrolizumab, a PD-1 inhibitor, demonstrated anti-tumour activity and tolerability
in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE …
in patients treated with sorafenib and with advanced hepatocellular carcinoma in KEYNOTE …
[HTML][HTML] Population ageing and mortality during 1990–2017: a global decomposition analysis
Background As the number of older people globally increases, health systems need to be
reformed to meet the growing need for medical resources. A few previous studies reported …
reformed to meet the growing need for medical resources. A few previous studies reported …
Unravelling the biology of SCLC: implications for therapy
Small-cell lung cancer (SCLC) is an aggressive malignancy associated with a poor
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
prognosis. First-line treatment has remained unchanged for decades, and a paucity of …
The global burden of melanoma: results from the Global Burden of Disease Study 2015
Background Despite recent improvements in prevention, diagnosis and treatment, vast
differences in melanoma burden still exist between populations. Comparative data can …
differences in melanoma burden still exist between populations. Comparative data can …
African genetic diversity and adaptation inform a precision medicine agenda
The deep evolutionary history of African populations, since the emergence of modern
humans more than 300,000 years ago, has resulted in high genetic diversity and …
humans more than 300,000 years ago, has resulted in high genetic diversity and …